|Articles|September 1, 2010
- BioPharm International-09-01-2010
- Volume 23
- Issue 9
BioPharm International, September 2010 Issue (PDF)
Combine Mechanistic Modeling and DoE to Streamline QbD
Advertisement
Articles in this issue
over 15 years ago
REMS Program Challenges Manufacturers, Providersover 15 years ago
Quality Management Systems for Small Biopharmaceutical Organizationsover 15 years ago
Biosimilars Approvals in the US: The Path Forwardover 15 years ago
Biosimilars, Part 3: Interchangeabilityover 15 years ago
Build Versus Buy in the Current Biotech Market EnvironmentNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
5
